Biofrontera AG represents diverse values and a strong corporate philosophy. Dedicated to innovation, Biofrontera AG strives to improve the lives of patients through advanced dermatological solutions. The company upholds the values of integrity, quality, and commitment in its pursuit of research, development, and commercialization of pharmaceuticals and medical devices. Biofrontera AG's corporate philosophy emphasizes scientific excellence, patient-centricity, and ethical conduct. With a focus on delivering effective and safe treatments, Biofrontera AG ensures its products meet rigorous standards to provide optimal care for individuals with dermatological conditions.

Biofrontera AG is primarily present in multiple countries and regions. As a global biopharmaceutical company, Biofrontera AG operates in Europe, specifically Germany, The Netherlands, Belgium, France, Italy, Spain, and Switzerland. Additionally, the company's presence extends to the United States, primarily targeting markets in the dermatology sector. Biofrontera AG's commitment to expanding its international footprint allows it to bring innovative dermatological solutions to patients worldwide.

Since its establishment, Biofrontera AG has achieved several significant milestones. The company gained FDA approval in 2012 for its flagship product, Ameluz®, used in the treatment of actinic keratosis. Biofrontera AG successfully launched Ameluz® in the European market in 2013, followed by its introduction in the US market in 2016. Moreover, the company received the European CE Mark approval for Ameluz® in combination with daylight photodynamic therapy in 2016. Over the years, Biofrontera AG has consistently demonstrated its commitment to developing and commercializing innovative dermatological products, positioning itself as a leading player in the field.

Biofrontera AG is a German biopharmaceutical company specializing in the development and commercialization of dermatological drugs. Founded in 1997, Biofrontera focuses on innovative therapies for the treatment of skin conditions and malignancies. The company is renowned for its flagship product Ameluz®, a prescription topical medication used in photodynamic therapy for the treatment of actinic keratosis and basal cell carcinoma. With a commitment to research and development, Biofrontera aims to improve patients' lives through effective and safe dermatological treatments. As a prominent player in the healthcare industry, Biofrontera AG has garnered recognition for its contributions to the field of dermatology.

The main competitors of Biofrontera AG in the market include pharmaceutical companies such as Sun Pharmaceutical Industries Ltd., Galderma Laboratories, and Johnson & Johnson.

Biofrontera AG is primarily active in the pharmaceutical industry.

The business model of Biofrontera AG revolves around the development, production, and commercialization of dermatological drugs and medical cosmetics. As a biopharmaceutical company, Biofrontera specializes in the treatment of skin conditions, including actinic keratosis and basal cell carcinoma. The company's innovative products are based on the proprietary formulation of the natural compound 5-aminolevulinic acid (ALA), which is activated through light exposure. By providing effective and safe treatment options, Biofrontera AG aims to improve the quality of life for patients suffering from skin diseases and to position itself as a leader in the dermatology market.

De Biofrontera K/W is 38,73.

De Biofrontera KUV is 0,27.

De AlleAktien Kwaliteitsscore voor Biofrontera is 3/10.

De verwachte Biofrontera omzet is 42,64 mln. EUR.

De verwachte Biofrontera winst is 296.469,33 EUR.

The Biofrontera AG is a German biotechnology company that specializes in the research, development, and marketing of innovative products for the treatment of skin diseases. The company was founded in 1997 and is headquartered in Leverkusen. Biofrontera's core business is the production and sale of medications for the treatment of actinic keratosis, a precursor to skin cancer. The company has developed an effective formulation based on Ameluz, which is capable of selectively destroying skin cells without affecting healthy tissue. In addition to therapy, Biofrontera also offers a wide range of dermatological products, including sunscreens, moisturizing creams, and specialized care products for patients with skin diseases. As an innovative company, Biofrontera focuses on constantly improving its products. To this end, it invests a significant portion of its revenue in research and development. Through this strategy, the company has already obtained numerous patents and approvals worldwide. To make its products more accessible to a broader customer base, Biofrontera is actively working on expanding into new markets, particularly in the United States and Europe. The company collaborates with leading clinics and experts in the field of dermatology to position its products in a targeted manner. In addition to selling its products through its own distribution network, Biofrontera also engages in strategic partnerships with other companies. The aim is to leverage synergies and jointly exploit new growth potentials. Overall, Biofrontera's business model focuses on offering innovative and high-quality products for the treatment of skin diseases, developed based on comprehensive research and development, as well as years of experience in dermatology. Through targeted expansion into new markets and strategic partnerships, the company aims to continue growing and expanding its customer base in the future.

Biofrontera keert een dividend van 0 EUR uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Biofrontera of het bedrijf keert geen dividend uit.

De ISIN van Biofrontera is DE0006046113.

Het WKN van Biofrontera is 604611.

De ticker van Biofrontera is B8FK.DE.

Binnen de laatste 12 maanden betaalde Biofrontera een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Biofrontera naar verwachting een dividend van 0 EUR betalen.

De dividendrendement van Biofrontera is momenteel .

Biofrontera betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Biofrontera betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 EUR verwacht. Dit komt overeen met een dividendrendement van 0 %.

Biofrontera wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Biofrontera van 16-9-2024 ter hoogte van 0 EUR te ontvangen, moest je het aandeel voor de ex-datum op 16-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 16-9-2024.

In het jaar 2023 heeft Biofrontera 0 EUR aan dividenden uitgekeerd.

De dividenden van Biofrontera worden in EUR uitgekeerd.